JUL 22, 2021 12:45 PM EDT

An Engineered AsCas12a nuclease facilitates the rapid generation of therapeutic cell medicines

C.E. Credits: Florida CE P.A.C.E. CE
Speaker

Abstract

Though AsCas12a fills a crucial gap in the current genome editing toolbox, it exhibits relatively poor editing efficiency, restricting its overall utility. In collaboration with Integrated DNA Technologies, we showed that this engineered variant we refer to as AsCas12a Ultra, increased editing efficiency to nearly 100% at all sites examined in HSPCs, iPSCs, T cells, and NK cells. We showed that AsCas12a Ultra maintains high on-target specificity thereby mitigating the risk for off-target editing and making it ideal for complex therapeutic genome editing applications. We achieved simultaneous targeting of three clinically relevant genes in T cells at >90% efficiency and demonstrated transgene knock-in efficiencies of up to 60%. We demonstrate site-specific knock-in of a CAR in NK cells, which afforded enhanced anti-tumor NK cell recognition, potentially enabling the next generation of allogeneic cell-based therapies in oncology. AsCas12a Ultra is an advanced CRISPR nuclease with significant advantages in basic research and in the production of gene edited cell medicines.

Learning Objectives:

1. Identify the engineered AsCas12a Ultra nuclease is commercially available to researchers from Integrated DNA Technologies

2. Recall this engineered AsCas12a nuclease forms the basis for EDIT-301, an experimental treatment for sickle cell disease which is currently being tested in the clinic

3. Recall this engineered AsCas12a nuclease breaks the observed paradigm where most natural and engineered CRISPR nuclease variants that achieve very high specificity come with a cost to on-target editing activity in most clinically relevant cell types


Show Resources
You May Also Like
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
SEP 16, 2021 8:00 AM PDT
C.E. CREDITS
SEP 16, 2021 8:00 AM PDT
Date: September 16, 2021 Time: 8:00am (PDT), 11:00am (EDT) Rapid screening and speed of scale-up in protein therapeutics are critical factors in today’s biotech and pharma workflows. T...
JUN 24, 2021 8:00 AM PDT
C.E. CREDITS
JUN 24, 2021 8:00 AM PDT
Date: June 24, 2021 Time: 8:00am (PDT), 11:00am (EDT) Cardiovascular disease is a leading health problem, affecting almost 30% of individuals in the developed world, and comprises a wide ran...
APR 20, 2021 4:30 PM PDT
C.E. CREDITS
APR 20, 2021 4:30 PM PDT
COVID-19 is a severe disease that has caused >1 million deaths in under one year. As this disease is novel, the molecular and cellular underpinnings of the progressive tissue injury are p...
Loading Comments...
Show Resources